Men's health at 40: the baseline lab panel every man should know

By the time a man turns 40, atherosclerosis may have been developing silently for 15 to 20 years. Insulin resistance accumulates without any clear warning. Blood pressure creeps up without symptoms. None of these processes announces itself until it reaches a threshold — and in many cases, the first signal is a cardiac event. Cardiovascular disease remains the leading cause of death among men in most high-income countries, and in the majority of cases it was quietly progressing long before it became visible.

A baseline lab panel at 40 is not about anxiety or checking everything at once. It is about establishing your personal reference point. When you know where your LDL, HbA1c, or testosterone sits today, any future deviation can be read as a trend — not as an isolated number without context. A single snapshot becomes the foundation for meaningful monitoring over the decades ahead.

This article outlines the screening panel that international guidelines — USPSTF, AHA/ACC, AUA, and ADA — recommend for men around the age of 40, with a brief explanation of what each test is asking and what conversation it opens with your doctor.

Baseline panel for men at 40

No doctor orders everything in one go — priorities depend on your risk factors, symptoms, and prior results. But the following covers the key cardiovascular, metabolic, and hormonal domains.

Test	What it screens for	Recommended frequency
Lipid panel (TC, LDL, HDL, TG)	Cardiovascular risk	Every 4–6 years (more often with risk factors)
HbA1c or fasting glucose	Type 2 diabetes / prediabetes	Every 3 years from age 35 (USPSTF/ADA)
Blood pressure (clinic)	Hypertension	Annually
TSH	Thyroid dysfunction	Symptom-driven
Total testosterone (AM, fasting)	Hypogonadism	Symptom-driven
Creatinine + eGFR	Kidney function	Annually with risk factors; otherwise every 2–3 years
ALT, AST, ALP, GGT	Liver health (esp. MASLD risk)	Every 2–3 years with obesity or metabolic syndrome
PSA (if shared decision)	Prostate cancer screening	After shared decision per AUA
Vitamin D (25-OH-D)	Deficiency status	Once at baseline; recheck only if abnormal
CBC (full blood count)	General haematological status	Combined with other panels

Most of these tests can be drawn in a single venous blood sample as part of a standard comprehensive panel. The logistics are minimal; the information yield is high.

Cardiovascular risk: lipid panel + risk calculator

A lipid panel is the starting point for cardiovascular risk assessment — but LDL on its own is necessary, not sufficient. The clinical picture only comes together when LDL is placed in the context of age, blood pressure, smoking status, diabetes, and family history.

Per the 2018 AHA/ACC guideline, men aged 40–75 with LDL cholesterol of 1.8–4.9 mmol/L (70–189 mg/dL) should have their 10-year atherosclerotic cardiovascular disease (ASCVD) risk calculated using the AHA Pooled Cohort Equations. Risk categories and their implications:

10-year ASCVD risk	Category	Approach
< 5%	Low	Lifestyle; recheck in 4–6 years
5–7.4%	Borderline	Statin discussion with additional risk factors
7.5–19.9%	Intermediate	Statin discussion; consider CAC in uncertain cases
≥ 20%	High	Statin therapy recommended

An important tool for men in the borderline or intermediate range: the coronary artery calcium (CAC) score (non-contrast cardiac CT). If CAC = 0, most men in these categories carry genuinely low risk and can reasonably defer statins. If CAC > 100, there is a compelling case for treatment even at borderline-intermediate calculated risk. CAC converts an ambiguous number into an actionable decision.

For a full breakdown of LDL, HDL, triglycerides, reference ranges, and how to read the atherogenic index — see LDL and HDL cholesterol: a complete guide to your lipid panel.

Metabolic screening: glucose + HbA1c

USPSTF (2021) recommends screening for prediabetes and type 2 diabetes in adults aged 35–70 who are overweight or obese (Grade B recommendation). Even without obesity, risk factors such as a family history of T2DM, hypertension, hypertriglyceridaemia, dyslipidaemia, or a sedentary lifestyle justify earlier or more frequent screening.

Screening methods — any of the following:

Marker	Normal	Prediabetes	Diabetes
HbA1c	< 5.7%	5.7–6.4%	≥ 6.5%
Fasting glucose	< 5.6 mmol/L (100 mg/dL)	5.6–6.9 mmol/L (100–125 mg/dL)	≥ 7.0 mmol/L (126 mg/dL)
75g OGTT (2-hour)	< 7.8 mmol/L (140 mg/dL)	7.8–11.0 mmol/L (140–199 mg/dL)	≥ 11.1 mmol/L (200 mg/dL)

If normal: repeat every 3 years. If prediabetes: more frequent follow-up and a conversation with your doctor about lifestyle intervention.

The practical takeaway: prediabetes at 40 is a window to act, not a verdict. The Diabetes Prevention Program (DPP) trial showed that structured lifestyle intervention — modest dietary changes plus 150 minutes per week of moderate aerobic exercise — reduced progression from prediabetes to type 2 diabetes by approximately 58%. This is one of the most robustly replicated results in preventive medicine.

For the full breakdown of HbA1c interpretation, diagnostic criteria, and how to prepare for the test — see HbA1c: what the result means for diabetes and prediabetes.

Hormonal screening: testosterone + PSA

Testosterone

Routine testosterone screening in all men at 40 is not recommended. Testing is indicated when symptoms are present that may point to hypogonadism:

• Persistent fatigue and low energy without an obvious cause
• Reduced libido or erectile dysfunction
• Loss of muscle mass despite consistent training
• Low mood, apathy, or difficulty concentrating
• Reduced body or facial hair

If symptoms are present, the test is drawn in the morning (7:00–10:00 AM), fasting. This timing is critical: testosterone follows a diurnal rhythm and peaks in the early morning hours — a mid-afternoon sample may fall below the lower reference limit even in a healthy man. A single low result is not a diagnosis. The Endocrine Society requires confirmation on two separate occasions, ideally weeks apart, before hypogonadism is established. The lower reference limit used by most guidelines and laboratories is approximately 10–12 nmol/L (300 ng/dL), though interpretation always requires clinical context rather than just the number.

PSA

Prostate-specific antigen (PSA) is a shared decision, not a blanket screening test. Routine PSA without discussion is not recommended — due to the risk of false positives, overdiagnosis, and potential harms from biopsy.

Per AUA (2023):

• Men 50–70: PSA discussion is appropriate after weighing the risks and benefits
• Men 45+ at elevated risk: Black men or those with a first-degree relative diagnosed with prostate cancer
• Men 40–45 with strong family history: a father or brother with prostate cancer — start the conversation now

If you have no family history of prostate cancer and are 40, you likely don’t need PSA yet. But this is a decision to make with your doctor, not to default on independently.

Kidney and liver: routine checks

Kidneys: creatinine + eGFR

Chronic kidney disease (CKD) is largely silent in its early stages. Kidneys can be functioning at 60–70% of capacity while a person feels entirely normal. The first detectable signal is typically a rising creatinine paired with a declining eGFR.

For healthy men without risk factors: check creatinine every 2–3 years as part of a comprehensive biochemistry panel. With hypertension, type 2 diabetes, obesity, or a family history of CKD: annual monitoring.

For a full explanation of eGFR stages, CKD classification, and what an elevated or low creatinine means — see Creatinine: normal range, eGFR, and what abnormal results mean.

Liver: ALT, AST, ALP, GGT

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is the most common silent liver pathology in men with overweight or metabolic syndrome. It produces no pain and can progress to steatohepatitis or fibrosis over years without symptoms.

If your BMI is above 25, you carry central adiposity, or your triglycerides exceed 1.7 mmol/L (150 mg/dL), including liver enzymes in your baseline check-up is warranted. Persistently elevated ALT or AST (more than 3 months, above 1.5× the upper limit of normal) warrants hepatology referral and abdominal ultrasound. An isolated modest rise after intense exercise is not pathological.

Family history: when to move screening earlier

Family history is not a source of anxiety — it is a clinical variable. It shifts screening earlier and increases frequency; it does not change which markers you test.

Situation	Action
Father had MI before 55 (mother before 65)	Consider Lp(a) once; 10-year ASCVD risk modelled more aggressively
T2DM in a parent or sibling	Screen from age 35 (not 45); annually if prediabetic
Father or brother with prostate cancer	Start PSA discussion at 40–45
First-degree relative with colorectal cancer	Colonoscopy from 40, or 10 years before the earliest family case
CKD in parents	Annual creatinine + urinalysis

One marker not in the standard panel that deserves a mention: lipoprotein(a), Lp(a). It is a genetically determined, largely lifestyle-resistant, independent cardiovascular risk factor — levels remain roughly stable throughout life and barely respond to diet. A one-time baseline measurement is recommended for anyone with a family history of premature cardiovascular disease or early MI in a first-degree relative. If Lp(a) exceeds 50 mg/dL (125 nmol/L), it meaningfully elevates cardiovascular risk and is factored into treatment decisions.

How HealthLab helps you track trends

A baseline lab panel at 40 is most valuable not as a one-off event but as the starting point for comparison. An LDL of 3.4 mmol/L (131 mg/dL) at 40 and the same value at 45 are two different stories depending on whether the number has been creeping up or holding steady over the intervening years. The trend is what your doctor can act on — but only if results are stored sequentially and consistently.

HealthLab automatically recognises biomarkers from PDF lab reports issued by any laboratory — LDL, HbA1c, testosterone, TSH, creatinine, ALT — and builds a trend chart over time. No manual data entry, no spreadsheets.

Download HealthLab on the App Store

Frequently Asked Questions

Do men at 40 need a PSA test if they have no symptoms?

For most men at 40 with no family history, no — not yet. AUA guidelines recommend initiating the PSA discussion between ages 50 and 70 (or from 45 for men at elevated risk). If your father or brother has had prostate cancer, discuss PSA with your doctor from age 40–45. The decision is always made jointly: your doctor explains the risk of false positives and overdiagnosis, and you weigh those against your personal situation.

What testosterone level counts as low?

Hypogonadism requires two things simultaneously: symptoms (fatigue, reduced libido, erectile dysfunction, muscle loss) and a confirmed low total testosterone on two separate morning fasting draws. Most guidelines use a lower reference limit of around 10–12 nmol/L (roughly 300 ng/dL), though the exact threshold varies by laboratory method and clinical context. A single low result without symptoms is not a diagnosis and not a reason to start treatment independently.

How often should I recheck a normal lipid panel?

For a man with no established cardiovascular disease and a low calculated risk: every 4–6 years. If risk factors are present — smoking, hypertension, diabetes, obesity, a family history of early heart disease — or if you start or adjust statin therapy, your doctor will recommend more frequent testing. Your first result at 40 creates the baseline that all future results will be compared against.

Do I need to fast before this baseline panel?

For a lipid panel: yes — the standard preparation is a 9–12 hour fast (water is fine). For fasting glucose: 8–10 hours. HbA1c and TSH do not require fasting, but since they are usually ordered alongside lipids, a single early-morning fasting draw covers everything neatly. Testosterone specifically requires a morning draw (7:00–10:00 AM) fasting, because levels peak in the early morning. Creatinine, liver enzymes, PSA, vitamin D, and a CBC have no meaningful fasting requirement, but drawing everything together in one morning session is the most practical approach.

---

This material does not replace clinical advice. Interpreting laboratory results always requires clinical context.